Depression and anxiety symptoms in female breast cancer survivors Mental and Behavioural Disorders Depressive episode, anxiety disorder, unspecified
Conditions
Interventions
Informed consent, screening questionnaire assessing inclusion and exclusion criteria, demographic information, and pre-treatment measures will be collected through a Qualtrics link which will be share
Sponsors
Trinity College Dublin
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Breast cancer survivors and their carers (people who support them such as a partner, family member, or friend) will be recruited online and screened for eligibility using Qualtrics. Survivors: 1. Female 2. Completed breast cancer treatment 3. At least mildly confident with using the internet 4. At least mildly confident in reading and writing in English Main carers: 1. Currently caring or have cared for a woman living with breast cancer (such as partner, spouse, friend, or relative of the patient) 2. At least mildly confident with using the internet 3. At least mildly confident in reading and writing in English
Exclusion criteria
Exclusion criteria: 1. Current suicidal ideation or intent 2. Current alcohol or drug misuse 3. Enduring mental health disorders such as schizophrenia, psychosis, and bipolar disorder 4. Currently being in treatment for depression or anxiety As it is a pilot study, no limit has been set for the time since the treatment completion or cancer stage as an exclusion criterion for survivors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Depression and anxiety symptoms measured using the Hospital Anxiety and Depression Scale (HADS) at pre-test, post-test, and 2-month follow-up | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Survivors' quality of life measured using a single item from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) at pre-treatment, post-treatment, and 2-month follow-up 2. Survivors’ use of coping styles for breast cancer-related stress measured by Brief COPE at pre-treatment, post-treatment, and 2-month follow-up 3. Survivors' cancer-related worries measured using Cancer Worry Scale at pre-treatment, post-treatment, and 2-month follow-up 4. Survivors' perceptions of social support measured using the Emotional/Informational subscale of the Modified Medical Outcomes Study Social Support Survey (MOS-SS) at pre-treatment, post-treatment, and 2-month follow-up 5. Survivors' and carers' communication quality measured using Survivor-Carer Cancer Communication at pre-treatment, post-treatment, and 2-month follow-up 6. Survivors' and carers' relationship quality measured using a single-item Relationship Quality scale at pre-treatment, post-treatment, and 2-month follow-up 7. Helpful aspects of the programme for survivors and carers measured using Helpful Aspects of Therapy Form (HAT) at post-treatment 8. Survivors' and carers' satisfaction with the programme measured using Satisfaction with Online Treatment (SAT) at post-treatment | — |
Countries
Ireland
Outcome results
None listed